With research showing that addictive behavior can be treated effectively with medication, ADial is developing compounds that affect the reward center of the brain, thereby decreasing the craving for alcohol and reducing alcohol consumption. Our medications appear to be effective based on a combination of an ability to leverage propriety targeted genetic efforts with synergistic treatment mechanisms –targeting multiple neurological pathways in the brain, thereby enhancing efficacy while reducing side effects. In addition, our compounds can be given to patients currently drinking, no abstinence prior to treatment required. This significant improvement not only increases access to treatment; it increases the likelihood of success, which can now be measured as a reduction in alcohol consumption and control over one’s drinking.